Myogen is a biopharmaceutical company founded in 1996, dedicated to advancing cardiovascular health with innovative small molecule therapeutics. Their slogan "Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs" reflects their mission. The company focuses on the discovery, development, and commercialization of small molecule therapeutics targeting cardiovascular disorders. With a strong emphasis on their advanced understanding of cardiovascular disease biology and clinical expertise in cardiovascular therapeutics, Myogen aims to address serious and debilitating cardiovascular disorders inadequately treated by existing therapies. The company's last investment was a $40.00M Series D investment on 29 August 2003, with participation from notable investors including New Enterprise Associates, Greenspring Associates, InterWest Partners, Sequel Venture Partners, JPMorgan Partners, CMEA Ventures, Pacific Rim Partners, and Perseus-Soros Biopharmaceutical Fund.
Myogen
Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs.
General Information
Get notified when Myogen moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Discover More
About Myogen
Taxonomy: biopharmaceutical company, cardiovascular health, small molecule therapeutics, discovery, development, commercialization, clinical expertise, cardiovascular disorders, biology of cardiovascular disease, clinical development expertise, novel therapies, licensing, acquisition, unmet medical needs
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | •••••• | 8 |
|
29 Aug 2003 |
| Series D | •••••• | 2 |
|
03 Jan 2002 |
| Series D | •••••• | - | 28 Aug 2001 | |
| Series D | •••••• | - | 01 Jun 2001 | |
| Venture Round | •••••• | - | 15 Dec 1999 |
Myogen Alternatives & Competitors
a leader in the development of comprehensive solutions for cardiovascular regenerative therapies
Anthos Therapeutics is a clinical-stage biopharma company developing innovative therapies for cardio...
FAQ About Myogen
Don't just browse. Track.
Signal Tracker monitors Myogen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.